RenalytixAI PLC
RenalytixAI PLC is an artificial intelligence-enabled in vitro diagnostics company based in New York, NY, dedicated to optimizing clinical management of kidney disease. Through its innovative KidneyIntelX platform, the company aims to improve patient outcomes and reduce healthcare costs by transforming risk assessment and clinical management practices for kidney disease.
Since its listing on AIM in November 2018, Renalytix has focused on addressing significant unmet needs in healthcare, leading to advancements such as the FDA approval of KidneyIntelX.dkd in June 2023. Recently, the company announced a collaboration with Tempus AI to enhance the availability of its prognostic blood testing for eligible patients across the Tempus US network of healthcare institutions.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.

